Appendix Table C74Comparative harms: oral selective antihistamine versus oral decongestant

Author, YearTreatment GroupN/nSedationHeadachePalpitationsInsomniaAnxiety
Bronsky, 1995Loratadine 10 mg217/21242311
Pseudoephedrine 240 mg220/21152694
Chervinsky, 2005aDesloratadine 5 mg214/20082
Pseudoephedrine 240 mg222/204611
Grosclaude, 1997Cetirizine 10 mg231/2316.14.300
Pseudoephedrine 240 mg226/2263.17.111.12.2
Grubbe, 2009Desloratadine 5 mg bc1987.13.0
Pseudoephedrine 240 mgde20012.014.0
Pleskow, 2005Desloratadine 5 mg37246111
Pseudoephedrine 240 mg37756373
Schenkel, 2002fDesloratadine 5 mg340/3402.11.50.60.6
Pseudoephedrine 240 mg342/3422.03.27.90.9
Sussman, 1999gFexofenadrine 120 mg218/21807.301.80
Pseudoephedrine 240 mg218/2181.412.42.812.81.4

N/n = Number of patients randomized/number of patients analyzed.

Symptom severity is unspecified unless otherwise noted (MILD, MOD = moderate, or SEV = severe).

a

Unclear if proportions of patients, or reports.

b

Other: no increased heart rate reported.

c

No serious or unexpected adverse events reported; 9 patients discontinued due to adverse events.

d

Other: increased heart rate: 3.0 BPM.

e

No serious or unexpected adverse events reported; 4 patients discontinued due to adverse events.

f

Number of reports.

g

Number of reports.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.